THE 2nd January marked the first day of trade for the newly independent biopharmaceutical company, AbbVie following its separation from Abbott. AbbVie employs 21,000 people across 40 countries, including 200 Australians and Kiwis in its Sydney and Wellington head offices. In Australia, the company has been around for 75 years, and globally it has been in existence for 125 years. In addition, Australia and NZ are in the top three contributors outside of the US in terms of numbers of sites and patients participating in AbbVie-supported clinical trials. As such there are nearly 5,500 patients enrolled in AbbViesupported clinical trials and studies at approximately 350 sites across Australia and NZ at any one time, in the areas of immunology, oncology and infectious disease. In the wake of its separation from Abbott, locally AbbVie Australia and NZ will launch with the following portfolio of biologics and specialty-focused medicines: HUMIRA (adalimumab), Lucrin (leuprorelin acetate), Kaletra (lopinavir/ ritonavir), Duodopa (levodopa/ carbidopa) and Sevorane (sevoflurane). Pictured above is the AbbVie team ringing the bell at the NYSE on Wall St for the first day of trade for 2013.